iNotify ApS

Notify Therapeutics is engaged in the discovery and development of drug products for treating infertility in women, based on the foundational science and intellectual property around new NTY series, which can utilize a new mechanism to promote egg formation and increase life birth.

The income statement for 2025 shows a loss of EUR 386 thousand against a loss of EUR 716 thousand last year, and the balance sheet at 31 December 2025 shows equity of EUR 692 thousand.

The loss for the year is according to expectations.…

No events materially affecting the Company's financial position have occurred subsequent to the financial year-end.

Rent and lease liabilities include rent liabilities totalling EUR 2 thousand with remaining contract terms of 3 months.

Contingent assets

The company has tax loss carry-forwards totalling EUR 582 thousand. The nominal value thereof is 22%, totalling EUR 128 thousand. The tax asset has not been recognised in the balance sheet due to the uncertainty as to application of the tax losses.